SynthesisThe Cochrane database of systematic reviews2000
Amodiaquine for treating malaria.
Synthesis in The Cochrane database of systematic reviews, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 119 citations in OpenAlex.
- A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc).PloS one · 2011Pooled it
- Children in reviews: methodological issues in child-relevant evidence syntheses.BMC pediatrics · 2005Pooled it
- In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated Plasmodium falciparum malaria in Malawi, 2014.Malaria journal · 2016Trial
- Chemoproteomics-based profiling elucidates the antimalarial effects of amodiaquine through disruption of glycolysis process in Plasmodium falciparum.Cell communication and signaling : CCS · 2026Article
- Article
- Sensitivity analysis with iterative outlier detection for systematic reviews and meta-analyses.Statistics in medicine · 2024Article
- Antiplasmodial activity of the natural product compounds alstonine and himbeline.International journal for parasitology. Drugs and drug resistance · 2021Article
- The orphan nuclear receptor Nurr1 agonist amodiaquine mediates neuroprotective effects in 6-OHDA Parkinson's disease animal model by enhancing the phosphorylation of P38 mitogen-activated kinase but not PI3K/AKT signaling pathway.Metabolic brain disease · 2021Article
- Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate-amodiaquine treatment of uncomplicated Plasmodium falciparum malaria in Zanzibar.Malaria journal · 2021Article
- Botanical candidates from Saudi Arabian flora as potential therapeutics forSaudi journal of biological sciences · 2021Review
- Pharmacokinetic profile of amodiaquine and its active metabolite desethylamodiaquine in Ghanaian patients with uncomplicated falciparum malaria.Malaria journal · 2021Article
- School-aged children based seasonal malaria chemoprevention using artesunate-amodiaquine in Mali.Parasite epidemiology and control · 2018Article
- Balancing drug resistance and growth rates via compensatory mutations in the Plasmodium falciparum chloroquine resistance transporter.Molecular microbiology · 2015Article
- Hematoxicity of amodiaquine in sprague-dawley rats.Toxicology international · 2012Article
- Current opinion on an emergence of drug resistant strains of Plasmodium falciparum through genetic alterations.Bioinformation · 2012Article
- In vitro amodiaquine resistance and its association with mutations in pfcrt and pfmdr1 genes of Plasmodium falciparum isolates from Nigeria.Acta tropica · 2011Article
- Identification of inhibitors of Plasmodium falciparum phosphoethanolamine methyltransferase using an enzyme-coupled transmethylation assay.BMC biochemistry · 2010Article
- Putting evidence into practice: how middle and low income countries "get it together".BMJ (Clinical research ed.) · 2004Review
- The contribution of clinical pharmacology to antimalarial drug discovery and development.British journal of clinical pharmacology · 2003Review
- Recent Advances in the Prophylaxis and Treatment of Malaria.Current infectious disease reports · 2001Article
Corrections and comments
- Updated by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmodiaquine has been widely used to treat malaria. Due to reports of fatal adverse drug reactions, discontinuation or modification of its use has been suggested.
objectivesThe objective of this review was to assess the effects of amodiaquine for treating malaria. SEARCH STRATEGY: We searched the Cochrane Infectious Diseases Group trials register and Medline. We also contacted researchers in the field and drug companies. SELECTION CRITERIA: Randomised and quasi-randomised trials comparing amodiaquine with other treatment for uncomplicated malarial infections in adults and children. DATA COLLECTION AND ANALYSIS: Both reviewers independently extracted data and assessed trial quality. MAIN
resultsForty trials were included. Allocation was adequately concealed in three trials. Amodiaquine was more effective than chloroquine for parasite clearance. The combined results of parasite clearance at seven days from 24 trials was 83% for amodiaquine and 56% for chloroquine (odds ratio 4.29, 95% confidence interval 3.51 to 5.24). The odds ratio for parasite clearance at 14 days was 6.00, 95% confidence interval 4.38 to 8.21. Amodiaquine and sulfadoxine/pyrimethamine showed similar results for parasite clearance on day seven, but sulfadoxine/pyrimethamine appeared to be more effective on day 14 and 28. No significant difference for adverse events was observed between amodiaquine and chloroquine and sulfadoxine/pyrimethamine. Reported adverse effects were minor or moderate, not life threatening. REVIEWER'S
conclusionsThere is some evidence to support the continued use of amodiaquine in the treatment of uncomplicated malaria, although drug resistance should be considered. Monitoring for toxicity should also continue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.